The new safety data from Phase III and I trials showing an absence of postinjection syndrome, a rare and serious side effect ...

As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...

With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced new positive efficacy, safety and ...

The FDA is poised to issue a decision soon on KarXT, a potential first-in-class antipsychotic for schizophrenia. What should ...

Newron today announces its financial and operational results for the half year ended June 30, 2024, and provides an update on ...

RVPH RECOVER Vocal Biomarker Data On September 4, 2024, Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) held a key ...

Neurocrine Biosciences announced that its ERUDITE Phase 2 trial for luvadaxistat failed to meet its primary endpoint in ...

Neurocrine Biosciences’ schizophrenia program pivot has failed. | Neurocrine Biosciences’ schizophrenia program pivot has ...

Explore the latest strides in schizophrenia treatment development as 2024 heralds a pivotal year, with promising collaborations and trials.

Recent research published in 2024 examined various tardive dyskinesia topics, including: transcranial direct current stimulation; new clinical tool for documenting and rating TD; and ...